An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury
Daniel Fernández-Llaneza,Romy M. P. Vos,Joris E. Lieverse,Helen R. Gosselt,Sandra L. Kane-Gill,Teun van Gelder,Joanna E. Klopotowska,the LEAPfROG Consortium,Ameen Abu-Hanna,Annemiek Dorgelo,Annette ten Teije,Birgit A. Damoiseaux,Cornelis Boersma,Dave A. Dongelmans,David H. de Koning,Erol S. Hofmans,Evelien Tiggelaar,Frank van Harmelen,Giovanni Cinà,Gerty Holla,Hilda J. de Jong,Iacopo Vagliano,Jan Pander,Jasper M. Boomker,Jurjen van der Schans,Kitty J. Jager,Linda Dusseljee-Peute,Luuk B. Hilbrands,Marianne le Comte,Marieke A. R. Bak,Mariette van den Hoven,Martijn G. Kersloot,Menno Maris,Nicolette F. de Keizer,Otto R. Maarsingh,Paul Blank,Piet Heingraaf,Ron Herings,Ron J. Keizer,Ronald Cornet,Ruben Boyd,Sebastiaan L. Knijnenburg,Sipke Visser,Stephanie Medlock,Tjerk S. Heijmens Visser,Vianda S. Stel,Wanda Konijn
DOI: https://doi.org/10.1007/s40264-024-01474-w
2024-09-28
Drug Safety
Abstract:The recent rise in acute kidney injury (AKI) incidence, with approximately 30% attributed to potentially preventable adverse drug events (ADEs), poses challenges in evaluating drug-induced AKI due to polypharmacy and other risk factors. This study seeks to consolidate knowledge on the drugs with AKI potential from four distinct sources: (i) bio(medical) peer-reviewed journals; (ii) spontaneous reporting systems (SRS); (iii) drug information databases (DIDs); and (iv) Nephro Tox website. By harnessing the potential of these underutilised sources, our objective is to bridge gaps and enhance the understanding of drug-induced AKI.
pharmacology & pharmacy,public, environmental & occupational health,toxicology